Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: past, present, and future

Luigi Mearini, Massimo Porena, Luigi Mearini, Massimo Porena

Abstract

Upon a review of recently published articles on high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer, we evaluated the current status of HIFU as a primary treatment option for localized prostate cancer and its use as salvage therapy when radiation failed. We also briefly discuss current issues in indications, definition of response, and finally the future of HIFU development.

Keywords: High intensity focused ultrasound; indications; outcomes; prostate cancer.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Yancik R. Population aging and cancer: A cross-national concern. Cancer J. 2005;11:437–41.
    1. Lynn LG, Putnam TJ. Histological and cerebral lesions produced by focused ultrasound. Ann J Pathol. 1944;20:637–49.
    1. Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: Effects on health-related quality of life. BJU Int. 2005;96:43–7.
    1. Pontones Moreno JL, Morera Martínez JF, Vera Donoso CD, Jiménez Cruz JF. Cryosurgery in the management of prostate cancer. Actas Urol Esp. 2007;31:211–32.
    1. Su AW, Jani AB. Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol. 2007;30:215–9.
    1. Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A. In vivo effects of high-intensity ultrasound on prostate adenocarcinoma. Cancer Res. 1992;52:6353–7.
    1. Madersbacher S, Kratzik C, Marberger M. Prostatic tissue ablation by transrectal high intensity focused ultrasound: Histological impact and clinical application. Ultrason Sonochem. 1997;4:175–9.
    1. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995;55:3346–51.
    1. Gelet A, Chapelon JY, Bouvier R, Souchon R, Pangaud C, Abdelrahim AF, et al. Treatment of prostate cancer with transrectal focused ultrasound: Early clinical experience. Eur Urol. 1996;29:174–83.
    1. Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M. Organ-confined prostate cancer: A proposed standard for the conduct of therapy. BJU Int. 2006;98:1187–92.
    1. Chaussy C, Thüroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep. 2003;4:248–52.
    1. Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF, et al. Eight years experience with high intensity focused ultrasonography for treatment of localized prostate cancer. Urology. 2008;72:1329–33.
    1. Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol. 2007;51:381–7.
    1. Thüroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, et al. High-intensity focused ultrasound and localized prostate cancer: Efficacy results from the European multicentric study. J Endourol. 2003;17:673–7.
    1. Wu F, Wang ZB, Jin CB, Zhang JP, Chen WZ, Bai J, et al. Circulating tumor cells in patients with solid malignancy treated by high-intensity focused ultrasound. Ultrasound Med Biol. 2004;30:511–7.
    1. Wu F, Wang ZB, Lu P, Xu ZL, Chen WZ, Zhu H, et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol. 2004;30:1217–22.
    1. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology. 2004;63:297–300.
    1. Murat FJ, Poissonnier L, Pasticier G, Gelet A. High-intensity focused ultrasound (HIFU) for prostate cancer. Cancer Control. 2007;14:244–9.
    1. Ficarra V, Antoniolli SZ, Novara G, Parisi A, Fracalanza S, Martigono G, et al. Short-term out come after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU. 2006;98:1193–8.
    1. Mearini L, D'Urso L, Collura D, Zucchi A, Costantini E, Formiconi A, et al. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: A preliminary report on the Italian experience. J Urol. 2009;181:105–11.
    1. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035–41.
    1. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using hig-intensity focused ultrasound. BJU Int. 2006;97:56–61.
    1. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, et al. First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol. 2008;53:1194–201.
    1. Beyer DC. The evolving role of prostate brachytherapy. Cancer Control. 2001;8:163–70.
    1. Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. Brachytherapy for carcinoma of the prostate: Techniques, patient seletion, and clinical outcomes. Semin Radiat Oncol. 2002;12:81–94.
    1. Zelefsky MJ, Yamada Y, Cohen GN, Shippy A, Chan H, Fridman D, et al. Five-year outcome of intraoperative conformal permanente I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:65–70.
    1. Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T, et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol. 2006;13:228–33.
    1. Misraï V, Rouprêt M, Chartier-Kastler E, Comperat E, Renard-Penna R, Haertig A, et al. Oncological control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J Urol. 2008;26:481–5.
    1. Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int. 2006;98:537–9.
    1. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, et al. PSA nadir is a significant predictor if treatment failure after high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur Urol. 2008;53:547–53.
    1. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B. Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol. 2006;24:585–90.
    1. Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouvière O, Curiel L, et al. Local recurrence of prostate cancer after external beam radiotherapy: Early experience of salvage therapy using high-intenbsity focused ultrasonography. Urology. 2004;63:625–9.
    1. Chaussy C, Thüroff S, Bergsdorf T. Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option in German. Urologe A. 2006;45:1271–5.
    1. Murat FJ, Poisonnier L, Rouviere O. Salvage high intensity focused ultrasound (HIFU) treatment for recurrent prostate cancer after radiation therapy: High efficacy in patients with good initial prognosis. J Urol. 2007;177:591.
    1. Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, et al. Mid-term Results Demonstrate Salvage High-Intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer. Eur Urol. 2009;55:640–9.
    1. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int. 2008;102:786–92.
    1. Paparel P, Curiel L, Chesnais S, Ecochard R, Chapelon JY, Gelet A. Synergistic inihinitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int. 2005;95:881–5.
    1. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. Male lumpectomy”: Focal therapy for prostate cancer using cryoablation. Urology. 2007;6:16–21.
    1. Lambert EH, Bolte K, Masson P, Katz AE. Focal cr yosurger y: Encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69:1117–20.
    1. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S. Focal therapy with high-intensity focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol. 2008;38:192–9.
    1. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol. 2007;4:632–42.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner